ストックスクリーナーアプリを入手
1.04
48.00%
-0.96
アフターアワーズ：
1.02
-0.02
-1.92%
前日終値:
$2.00
開ける：
$1.18
24時間の取引高:
9.23M
Relative Volume:
21.86
時価総額：
$65.27M
収益：
-
当期純損益:
$-41.07M
株価収益率:
-1.5758
EPS:
-0.66
ネットキャッシュフロー:
$-32.97M
1週間 パフォーマンス:
-50.71%
1か月 パフォーマンス:
-63.06%
6か月 パフォーマンス:
-57.02%
1年 パフォーマンス:
-39.18%
1日の値動き範囲:
$0.726
$1.50
1週間の範囲:
$0.726
$2.36
52週間の値動き範囲:
$0.726
$4.2684
Galectin Therapeutics Inc Stock (GALT) Company Profile
名前
Galectin Therapeutics Inc
セクター
電話
678-620-3186
住所
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
GALT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
1.04 | 65.27M | 0 | -41.07M | -32.97M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-08-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-13 | 開始されました | B. Riley FBR | Buy |
| 2017-12-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-10-19 | 開始されました | ROTH Capital | Buy |
| 2017-03-30 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | ダウングレード | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | ダウングレード | ROTH Capital | Buy → Sell |
| 2016-03-28 | 再開されました | H.C. Wainwright | Buy |
| 2015-09-21 | 開始されました | H.C. Wainwright | Buy |
| 2014-08-01 | ダウングレード | Aegis Capital | Buy → Hold |
| 2014-07-30 | 繰り返されました | MLV & Co | Buy |
| 2014-07-29 | 繰り返されました | MLV & Co | Buy |
| 2014-04-02 | 繰り返されました | MLV & Co | Buy |
| 2014-02-10 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-09 | 繰り返されました | Aegis Capital | Buy |
| 2013-12-03 | 開始されました | MLV & Co | Buy |
| 2013-08-19 | 繰り返されました | Aegis Capital | Buy |
すべてを表示
Galectin Therapeutics Inc (GALT) 最新ニュース
Belapectin shows promise in liver disease trial - Investing.com India
Dow Surges Over 600 Points, Gold Jumps 1.5% - Benzinga
Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint - MarketWatch
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Galectin Therapeutics stock hits 52-week low at $1.23 - Investing.com
Phase III MASH Miss Sends Galectin Stock Tumbling - BioSpace
Dow Surges 100 Points, Carnival Earnings Top Views - Benzinga
Belapectin shows promise in liver disease trial By Investing.com - Investing.com South Africa
Galectin stock drops after MASH trial data (GALT:NASDAQ) - Seeking Alpha
Galectin's Belapectin Shows 48.9% Reduction in MASH Cirrhosis Trial, Mixed Endpoint Results - StockTitan
Gilead and Terray Therapeutics collaborate on drug discovery - BioWorld Online
The Pharma Bro Martin Shkreli Wants You To Short Bitcoin, MicroStrategy, And Quantum Computing Stocks - Wccftech
Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - Defense World
Non-Alcoholic Steatohepatitis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight - EIN News
Stock Traders Buy High Volume of Put Options on Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Short Mafia Attacking Galectin Therapeutics (NASDAQ : GALT) Ahead of Planned Year-End Readout - Insider Financial
Liver Cirrhosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports - EIN News
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks - Yahoo Finance
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Full Stock Market News from 2024-12-06 - StockTitan
GALT (Galectin Therapeutics) E10 : $-0.72 (As of Sep. 2024) - GuruFocus.com
Psoriasis Pipeline Therapeutics Assessment Report 2024 (Updated) - openPR
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
Bank of America Corp (BAC-N) QuotePress Release - The Globe and Mail
StockNews.com Upgrades Galectin Therapeutics (NASDAQ:GALT) to "Hold" - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com - Defense World
Non-alcoholic Steatohepatitis Treatment Market Projected to Show Strong Growth - openPR
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times
Galectin Therapeutics Advances NAVIGATE Trial for MASH Cirrhosis Treatment, December Readout on Track | GALT Stock News - StockTitan
HC Wainwright Analysts Decrease Earnings Estimates for GALT - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Earns Buy Rating from HC Wainwright - MarketBeat
Galectin Therapeutics Reports Increased Q3 Losses - TipRanks
Galectin Therapeutics Inc (GALT) Quarterly 10-Q Report - Quartzy
Galectin Therapeutics Advances Galectin-Based Therapeutics Pipeline - TipRanks
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - The Manila Times
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21 - The Manila Times
Galectin Q3 Loss Narrows to $11.2M; Key NAVIGATE Trial Results Due December | GALT Stock News - StockTitan
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight - The Malaysian Reserve
Galectin Therapeutics (NASDAQ: GALT): Disrupting Merck’s Cancer Dominance - Insider Financial
Individual investors who hold 54% of Galectin Therapeutics Inc. (NASDAQ:GALT) gained 12%, insiders profited as well - Simply Wall St
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
Non-Alcoholic Steatohepatitis Market to Show Remarkable - openPR
Psoriasis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Recent Developments | Astrazeneca, Bayer, Sanofi, Pfizer, Merck, Novartis - Barchart
Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, - openPR
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Galectin therapeutics director Eldred Kary buys $1,300 in stock By Investing.com - Investing.com South Africa
Galectin therapeutics director Eldred Kary buys $1,300 in stock - Investing.com
Galectin Therapeutics Inc (GALT) 財務データ
収益
当期純利益
現金流量
EPS
Galectin Therapeutics Inc (GALT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| FREEMAN KEVIN D | Director |
Oct 17 '24 |
Buy |
2.64 |
1,300 |
3,432 |
34,769 |
| FREEMAN KEVIN D | Director |
Oct 16 '24 |
Buy |
2.70 |
5,000 |
13,500 |
80,000 |
| FREEMAN KEVIN D | Director |
Oct 16 '24 |
Buy |
2.70 |
5,000 |
13,500 |
33,469 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):